BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16730134)

  • 1. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
    Schild SE; McGinnis WL; Graham D; Hillman S; Fitch TR; Northfelt D; Garces YI; Shahidi H; Tschetter LK; Schaefer PL; Adjei A; Jett J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1106-11. PubMed ID: 16730134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
    Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
    J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
    Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
    Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
    Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-21-S12-26. PubMed ID: 9331115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.
    Comella G; Frasci G; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Ruffolo P; Comella P
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-113-S12-116. PubMed ID: 9331134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
    Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
    Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
    Jeremić B; Milicić B; Acimović L; Milisavljević S
    J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study.
    Endo M; Takada Y; Obayashi K; Kotani Y; Satouchi M; Kado T; Sugimura K
    Radiat Med; 2005 Aug; 23(5):331-5. PubMed ID: 16342905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
    J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.